<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="nivolumab [12], obinutuzumab [13], brentuximab [14]. Anticancer non-protein-based treatment with" exact="oxaliplatin" post="[15] and IMiDs (lenalidomide) [16] can activate cytokine storm"/>
 <result pre="Placebo-controlled Multi-center Study to Assess the Efficacy and Safety of" exact="Ruxolitinib" post="in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID) (RUXCOVID)"/>
 <result pre="(RUXCOVID) (RUXCOVID) R NCT04362137 Multicentric (62 centers) worldwide Phase 3" exact="Ruxolitinib" post="for the Treatment of Acute Respiratory Distress Syndrome in"/>
 <result pre="NCT04361903 Pisa, Italy Treatment of SARS Caused by COVID-19 With" exact="Ruxolitinib" post="R NCT04334044 Huixquilucan, Mexico Phase 1/2 Baricitinib in Symptomatic"/>
 <result pre="Signals C NCT01752348 Aarhus C, Denmark Prevention and Treatment With" exact="Calcifediol" post="of COVID-19 Induced Acute Respiratory Syndrome (COVIDIOL) IP NCT04366908"/>
 <result pre="function of existing TH17 cells. Treatment with the JAK1/2 inhibitor" exact="ruxolitinib" post="signiï¬�cantly reduced the symptoms of disease and prolonged survival"/>
 <result pre="of disease and prolonged survival time in experimental murine model." exact="Ruxolitinib" post="diminished pro-inflammatory cytokine production, mitigating the cytokine-driven hyperinflammation that"/>
 <result pre="experimental work supports the integration of JAK inhibitors such as" exact="ruxolitinib" post="into clinical trials as a novel strategy to counteract"/>
 <result pre="August 2020) focusing on treatment COVID-19 associated cytokine storm with" exact="ruxolitinib" post="as monotherapy (NCT04362137, NCT04361903, NCT04334044 - see Table 1)."/>
 <result pre="us to use them in the treatment of cytokine storm." exact="N-acetylcysteine" post="(NAC) serves as a prodrug to L-cysteine and L-cysteine"/>
 <result pre="was published by Han et al. [48]. Sodium cromoglycate or" exact="ketotifen" post="generally used to treat allergic diseases, significantly inhibit degranulation"/>
 <result pre="Other experimental study evaluated mast cell degranulation after cromoglycate and" exact="ketotifen" post="in rat liver resulting in decreased levels IL-6 and"/>
 <result pre="highly pathogenic H5N1 influenza A virusBiochem Pharmacol.793201041342010.1016/j.bcp.2009.08.025(2010)19732754 45JangY.Y.SongJ.H.ShinY.K.HanE.S.LeeC.S.Depressant effects of" exact="ambroxol" post="and erdosteine on cytokine synthesis, granule enzyme release, and"/>
 <result pre="macrophages activated by lipopolysaccharidePharmacol Toxicol.924200317317910.1034/j.16000773.2003.920407.x12753420 46DemiralayR.GÃ¼rsanN.ErdemH.The effects of erdosteine and" exact="N-acetylcysteine" post="on apoptotic and antiapoptotic markers in pulmonary epithelial cells"/>
 <result pre="of mast cell degranulation, oxidative stress, proinflammatory cytokine, and inducible" exact="nitric oxide" post="synthaseDrug Des Devel Ther.16920155237524610.2147/DDDT.S88337 50GelerisJ.SunY.PlattJ.ZuckerJ.BaldwinM.Observational Study of Hydroxychloroquine in"/>
 <result pre="inducible nitric oxide synthaseDrug Des Devel Ther.16920155237524610.2147/DDDT.S88337 50GelerisJ.SunY.PlattJ.ZuckerJ.BaldwinM.Observational Study of" exact="Hydroxychloroquine" post="in Hospitalized Patients with Covid-19N Engl J Med.7202010.1056/NEJMoa2012410NEJMoa2012410 51HeG.LiQ.LiW.RuanY.XiongX.Effect"/>
 <result pre="Pharmacol.685201247950310.1007/s00228-011-1161-x22105373 53CecrdlovaE.PetrickovaK.KolesarL.PetricekM.SekerkovaA.Manumycin A downregulates release of proinflammatory cytokines from TNF" exact="alpha" post="stimulated human monocytesImmunol Lett.169201681410.1016/j.imlet.2015.11.01026602157 54DarwishI.MubarekaS.LilesW.C.Immunomodulatory therapy for severe influenzaExpert"/>
</results>
